Biontech Se Sponsored Adr Stock News

Additional manufacturing site for COVID-19 vaccine Janssen EMAs human medicines committee (CHMP) has approved an additional manufacturing site for the production of COVID-19 Vaccine Janssen, developed by Janssen-Cilag International NV. The site, located in Marcy-lÉtoile, France, and operated by Sanofi Pasteur, will manufacture finished product. The site is expected to support the continued supply of []

In most Balkan countries, the situation with the spread of the coronavirus remains worrying. In some countries, the incidence is declining, but in others, the prevalence of coronavirus remains high. The new variant of COVID-19 Omicron, which has already been detected in seven countries - Turkey, Romania, Greece, Croatia, Slovenia, Montenegro, Cyprus - is of great concern. ALBANIA More than 300 new cases of COVID-19 have been registered in Albania in recent days. There are not many deaths in the country (several people a day). Since the beginning of the pandemic in Albania, nearly 205,000 cases of coronavirus infection have been registered and more than 3,150 people have died. To date, 2.22 million doses of COVID-19 vaccine have been administered in the country. 998 thousand people or 35 percent of the country''s population have been fully vaccinated. The vaccines of Pizer / Biontech, AstraZeneca, the Russian Sputnik V and the Chinese CoronaVac of the Sinovac company are allowed to be administered in Albania.

European Union governments have agreed to exercise an option to buy more than 180 million doses of a version of the COVID-19 vaccine adapted for the Omicron variant developed by BioNTech and Pfizer, the head of the European Commission said. Pfizer and BioNTech began development of a prototype Omicron-specific vaccine

BioNTech SE (BNTX) is one of the biggest beneficiaries of the pandemic, as it launched the German company to global success while reporting record revenues quarter after quarter in FY2021. With the bi

Pfizer and BioNTech announced on Thursday evening that they had submitted an application to the Food and Drug Administration (FDA) seeking full approval for the administration of their two-dose COVID-19 vaccine in childre

All of these vaccine stocks benefited from rising concerns about the Omicron variant.

Vaccine advisers to the US Centers for Disease Control and Prevention voted 15-0 Thursday to change recommendations for Covid-19 vaccines to make clear that shots made by Moderna and Pfizer/BioNTech are preferred over Johnson & Johnson''s vaccine.

RIO DE JANEIRO, BRAZIL - Anvisa, Brazil''s regulatory body, authorized this Thursday for the first time the vaccination of children against Covid-19 with the immunizer from Pfizer/BioNTech. However, the Ministry of Health lacks specific doses intended for people between 5 and 11 years of age. The regulatory agency made a series of technical recommendations to [] The post Pfizer Covid vaccine authorized in Brazil for children between 5 and 11 years of age appeared first on The Rio Times .

That''s the same age range applied to the shot developed by Pfizer Inc and BioNTech, which has been given out about 93,000 times as a booster through Wednesday, taking in about 0.1% of the population. Novavax''s protein-based vaccine was submitted to regulators by its Japanese distributor Takeda Pharmaceutical Co., the company said in a statement.

Early trials show jab effective in people of all ages who have already received doses of any vaccine Coronavirus latest updates See all our coronavirus coverage Efforts by the French and British drugmakers GSK and Sanofi Pasteur to produce a Covid-19 vaccine have suffered a further setback, with final clinical data on the jab and a potential launch delayed until next year as they struggle to find enough uninfected people to test it on. The two vaccine specialists announced positive preliminary results from a trial that showed the vaccine raised antibody levels against Covid by nine to 43 times when given as a single booster shot in people who had already received doses of AstraZeneca, Johnson & Johnson, Moderna or Pfizer/BioNTech vaccines, for all age groups. Continue reading

The Omicron variant has made Wuhan based vaccines redundant, will replace Delta, and causes a milder version of covid. BioNTech, Novavax and Moderna will need to urgently develop an appropriate 2nd ge

By Francesco Guarascio BRUSSELS (Reuters) - Pfizer and BioNtech are set to displace AstraZeneca as the main suppliers of COVID-19 vaccines to the global COVAX programme at the start of 2022, a shift that shows the increasing importance of their shot for poorer states. The expected change comes with headaches for receiving countries that lack sufficient cold stora